Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DNM2 | P50570 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553098 | 0.85 | HTR6 (0.41) | HTR6CNR2ALDH1A1PDE4APDE4B | |
| SCHEMBL13354930 | 0.72 | CYP1A2 (0.56) | TOP2ACNR2ALDH1A1CYP1A2POLB | |
| SCHEMBL4429023 | 0.71 | HTR6 (0.55) | HTR6TOP2A | |
| SCHEMBL4426419 | 0.71 | HTR6 (0.51) | HTR6ALDH1A1CYP1A2POLB | |
| SCHEMBL4418543 | 0.70 | KMT2A (0.43) | HTR6TOP2ACNR2ALDH1A1CYP1A2 | |
| SCHEMBL4422242 | 0.70 | HTT (0.40) | HTR6CNR2ALDH1A1POLB | |
| SCHEMBL6421284 | 0.70 | CNR2 (0.57) | CNR2ALDH1A1 | |
| SCHEMBL4417556 | 0.69 | PDE4A (0.39) | HTR6ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL4429045 | 0.68 | PKM (0.40) | HTR6TOP2ACNR2ALDH1A1CYP1A2 | |
| SCHEMBL25316072 | 0.68 | CNR2 (0.56) | CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608717-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-10-27 | — | — | US | disclosed |
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| US-7291736-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
| US-20050020596-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885TOP2A 2603/4885DNM1 3023/4885 |
| US-20050020596-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885TOP2A 2603/4885DNM1 3023/4885 |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1B | HTR6 1/4885TOP2A 3503/4885DNM1 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.